Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person
   Bohnen Shane

   (Last)       (First)       (Middle)
   614 MCKINLEY PLACE NE
   MINNEAPOLIS MN 55413

2. Issuer Name and Ticker or Trading Symbol
   BIO-TECHNE Corp [ TECH ]

3. Date of Earliest Transaction (Month/Day/Year)
   08/15/2023

4. If Amendment, Date of Original Filed (Month/Day/Year)
   08/17/2023

5. Relationship of Reporting Person(s) to Issuer
   Director
   Officer (give title below)
   Other (specify below)
   SVP - General Counsel

6. Individual or Joint/Group Filing (Check Applicable Line)
   X Form filed by One Reporting Person
   Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)

2. Transaction Date (Month/Day/Year)

3. Deemed Execution Date, if any (Month/Day/Year)

4. Transaction Code (Instr. 8)

5. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)

6. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)

7. Ownership Code (Instr. 4)

8. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)

9. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)

2. Conversion or Exercise Price of Derivative Security

3. Transaction Date (Month/Day/Year)

4. Deemed Execution Date, if any (Month/Day/Year)

5. Transaction Code (Instr. 8)

6. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)

7. Date Exercisable and Expiration Date (Month/Day/Year)

8. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)

9. Price of Derivative Security (Instr. 5)

10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)

11. Nature of Indirect Beneficial Ownership (Instr. 4)

<table>
<thead>
<tr>
<th>Security</th>
<th>Date</th>
<th>Code</th>
<th>Number</th>
<th>Expiration Date</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Restricted Stock Units</td>
<td>08/15/2023</td>
<td>A</td>
<td>4,802</td>
<td>$4.802</td>
<td></td>
</tr>
<tr>
<td>Stock Option (Right to Buy)</td>
<td>08/15/2023</td>
<td>A</td>
<td>12,924</td>
<td>$4.802</td>
<td></td>
</tr>
</tbody>
</table>

Explanation of Responses:
1. Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
2. Vests in full or in part on 8/15/2026 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).

Remarks:
This amendment is being filed to correct the number of restricted stock units and performance options being granted.

/s/ Shane Bohnen

Date: 12/14/2023

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).


Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.